A Review of Alzheimers Diseases

Authors

  • Kavya K V.V. Institute of Pharmaceutical Sciences, Gudlavalleru, Krishna District – 521356, Andhra Pradesh, India http://orcid.org/0000-0002-9202-5410
  • Sajja Jayanth Babu V.V. Institute of Pharmaceutical Sciences, Gudlavalleru, Krishna District – 521356, Andhra Pradesh, India
  • Galiveeti Karunakar Department of Pharmaceutics, Vasavi Institute of Pharmaceutical Sciences, Vasavi Nagar, Peddapalli (Village), Sidhout (Mandal), YSR Kadapa (Dist) – 516247, Andhra Pradesh, India
  • Lakshmana Rao A Department of Pharmaceutics, Vasavi Institute of Pharmaceutical Sciences, Vasavi Nagar, Peddapalli (Village), Sidhout (Mandal), YSR Kadapa (Dist) – 516247, Andhra Pradesh, India

DOI:

https://doi.org/10.26452/fjphs.v3i1.335

Abstract

Alzheimer’s disease, recognized just like an accelerated multifaceted neurological condition, is the primary reason for Alzheimer’s disorder in early adulthood. Over the last 20 years, progress in the pathogenesis field has influenced the study’s authors for the investigative process of novel medicinal therapeutics focused on the pathogenetic occurrences of such disorders. Such substances slow down the progression of the disease and focus on providing indicative relief even though they fail to produce a significant indication remedy. Whereas the neurodegenerative characteristics of Alzheimer’s disorder have been identified, the intricate details of such a process have still not been firmly established. The above lack of comprehension considering the pathogenic method could be the probable explanation for such non-availability after all successful treatments, which can protect against incidence and development after all disorders. Due mainly to the growth opportunity in the ground of pathogenic mechanisms in the last several years, new therapy goals can be found should deliver the underlying medical condition of being addressed directly. Throughout this summary, publishers may analyze the different elements of pathogenetic methods underneath Alzheimer’s disorder and its control via conventional drug treatment and advanced investigational treatment approaches, recently concluded and continuing.

Keywords:

Acetylcholinesterase Inhibition, Alzheimer’s Disorder, Amyloid Beta, N-Methyl D-Aspartate Adrenergic Receptor, Fibrillary

Downloads

Download data is not yet available.

Published

2023-01-04

How to Cite

Kavya K, Sajja Jayanth Babu, Galiveeti Karunakar, & Lakshmana Rao A. (2023). A Review of Alzheimers Diseases. Future Journal of Pharmaceuticals and Health Sciences, 3(1), 11–21. https://doi.org/10.26452/fjphs.v3i1.335

Issue

Section

Review Articles

Most read articles by the same author(s)